Next-generation sequencing (NGS) has revolutionised genomics research. This massively parallel sequencing technology offers ultra-high throughput, scalability and speed. It has enabled the accurate diagnosis of human diseases and the selection of molecular target drugs for individual treatments. In light of the pandemic, perhaps the most recognised applications of NGS in recent times are the tracking of SARS-CoV-2 variants and the roll-out of COVID-19 vaccination programs worldwide.
The NGS market is starting to enter a more dynamic phase, which is raising some important questions: What are the emerging forces that could influence the future of sequencing? How will this revitalised market affect the purchasing of sequencing technology? How does competition in the NGS market, now or in the future, impact the wider fields of research and healthcare? What ethical issues need to be considered as we enter the next era of genomic sequencing?
Why attend this webinar?
This webinar will bring together a panel of experts to address these queries, each with different experiences and perspectives within the NGS field. By attending you will:
- Gain a greater understanding of the current sequencing landscape
- Enhance your knowledge about how and why the market is set to shift in the future
- Better prepare yourself to adapt your work and sequencing workflow in the coming years
- Learn about how the evolution of NGS may create some new and persistent ethical issues
There will also be plenty of time for Q&A!
· Shawn Baker, Genomics Start-up Advisor/Investor/Consultant, SanDiegOmics
· Tiffany Boughtwood, Managing Director, Australian Genomics
· David Smith, Emeritus Professor, Mayo Clinic
· Natalie Thorne, Innovation & Technology Lead, Melbourne Genomics Health Alliance
Register for this webinar: